Create account

Coverage dated October 21, 2026 to October 23, 2026

Moderna Stock Plunges 25% After Possible Cancer Vaccine Data Leak

Headline from Forbes

The drop is a sharp reversal of a massive 2026 stock rally fueled by optimism over its personalized cancer vaccine.

Forbes's own description from its feed. We collect headlines and these descriptions, not full articles; read the original reporting below.

Read the reports

Reports & sources

8 articles, oldest first.

  1. Just the News

    Moderna stock plummets after reported leak of disappointing cancer-vaccine data (opens Just the News)

    Published

    Just the News's feed description

    The shares dropped by nearly 18% at the close of the day, according to the Wall Street Journal, as apparently positive results still fell short of expectations.

  2. Bloomberg

    Moderna, Merck Shares Fall After Possible Melanoma Data Leak (opens Bloomberg)

    Published

    Bloomberg's feed description

    Shares of Moderna Inc. and Merck & Co. fell after reports emerged about the results of the companies’ widely anticipated personalized melanoma vaccine, suggesting a possible leak of the data that’s slated to be released this weekend.

  3. Investor's Business Daily

    Moderna Crashes 20% On Reportedly Leaked Cancer Vaccine Data (opens Investor's Business Daily)

    Published

    Investor's Business Daily's feed description

    Moderna stock crashed Thursday after a third-party leaked the purported cancer vaccine data ahead of a hotly anticipated presentation.

  4. Forbes

    Moderna Stock Plunges 25% After Possible Cancer Vaccine Data Leak (opens Forbes)

    Published

    Forbes's feed description

    The drop is a sharp reversal of a massive 2026 stock rally fueled by optimism over its personalized cancer vaccine.

  5. Financial Times

    Moderna shares sink after leaked cancer data missed expectations (opens Financial Times)

    Published

    Financial Times's feed description

    Melanoma vaccine treatment cut risk of recurrence or death by 58% but failed to exceed Wall Street’s lofty expectations

  6. Bloomberg

    Oncologists Cheer Melanoma Data That Tanked Moderna’s Shares (opens Bloomberg)

    Published

    Bloomberg's feed description

    Leaked data from Moderna Inc. and Merck & Co.’s highly anticipated melanoma vaccine trial has led to a rare disconnect between doctors, who celebrated the result, and Wall Street, which sold off the stocks.

  7. Cheddar

    Moderna's Cancer Vaccine Breakthrough Meets a Wall Street Meltdown (opens Cheddar)

    Published

    Cheddar's feed description

    Moderna shares plunged after details of its experimental cancer vaccine trial leaked ahead of a scheduled presentation, even though the results were positive.

  8. Investor's Business Daily

    Merck And Moderna Diverge On Cancer Vaccine Results. Do They Still Have A Viable Drug? (opens Investor's Business Daily)

    Published

    Investor's Business Daily's feed description

    Moderna and Merck stock diverged Friday as investors digested the early release of their cancer vaccine data.

Related updates

Separate coverage close to this update in time and subject.

Moderna Stock Plunges 25% After Possible Cancer Vaccine Data Leak | Since Then